Literature DB >> 22690731

Risk adjustment of heroin treatment outcomes for comparative performance assessment in England.

John Marsden1, Brian Eastwood, Hayley Jones, Colin Bradbury, Matthew Hickman, Jonathan Knight, Kulvir Randhawa, Martin White.   

Abstract

AIMS: Variability in effectiveness of treatment for substance abuse disorder (SUD) is an important and understudied issue. This study aimed to quantify the extent of outcome variability in the English SUD treatment system after adjusting for potential confounding variables.
DESIGN: Prospective cohort study using data from the English national drug treatment outcome monitoring database.
SETTING: All 149 administrative areas delivering publicly funded SUD services in the National Health Service and non-governmental sector. PARTICIPANTS: New adult admissions between January 2008 and October 2010 with illicit heroin-related problems in all administrative areas, with an in-treatment review conducted between 5 and 26 weeks (mean = 129.5 days; SD = 40.0) up to 30 April 2011 (n = 65 223; 75.6% of eligible clients). Individuals were divided randomly to form model developmental and internal validation samples. These were contrasted with an independent (external) sample of the same population admitted to treatment between November 2010 and April 2011 and followed to 31 October 2011 (n = 13 797; 81.4% of those eligible). MEASUREMENTS AND ANALYSIS: The outcome measure was self-reported illicit heroin use, categorized as abstinent or deteriorated (the latter by Reliable Change Index), each risk-adjusted by person-level (demographics, clinical severity and treatment complexity) and area-level (SUD prevalence, social deprivation and severity averages) covariates by multivariable logistic regression using multiply imputed outcome and covariate data. Risk-adjusted models were assessed by information criteria and discrimination (c-index). Standardized outcome rates were compared by funnel plot with 95% and 99% control limits.
FINDINGS: Models of heroin abstinence (48.4%) and deterioration (3.2%) were comparable across the developmental and validation samples (c-index = 0.70-0.71 and 0.82-0.87), with 79.2 and 94.0%, respectively, of the 149 treatment areas falling within 95% control limits. At the 99% limit, seven areas (4.7%) achieved abstinence rates above the national average, and eight had relatively poor abstinence rates (5.4%). At the 99% control limit, one area achieved very low deterioration outcomes and two (1.3%) were worse that the average. Risk adjustment served to increase abstinence rates in good performing areas by 0.63% and reduce abstinence rates by 0.37% in poor performing areas, and by 0.12% and 0.18%, respectively, for deterioration.
CONCLUSION: There is some exceptional variability in the apparent effectiveness of the English treatment system for substance use disorders. It is important to determine the source of this variability in order to inform drug treatment delivery and its evaluation both in England and overseas.
© 2012 The Authors, Addiction © 2012 Society for the Study of Addiction.

Entities:  

Mesh:

Year:  2012        PMID: 22690731     DOI: 10.1111/j.1360-0443.2012.03971.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  6 in total

1.  Measurement-based care using DSM-5 for opioid use disorder: can we make opioid medication treatment more effective?

Authors:  John Marsden; Betty Tai; Robert Ali; Lian Hu; A John Rush; Nora Volkow
Journal:  Addiction       Date:  2019-01-30       Impact factor: 6.526

2.  Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone.

Authors:  John Marsden; Mike Kelleher; Eilish Gilvarry; Luke Mitcheson; Zoë Hoare; Dyfrig Hughes; Jatinder Bisla; Angela Cape; Fiona Cowden; Edward Day; Jonathan Dewhurst; Rachel Evans; Andrea Hearn; Joanna Kelly; Natalie Lowry; Martin McCusker; Caroline Murphy; Robert Murray; Tracey Myton; Sophie Quarshie; Gemma Scott; Sophie Turner; Rob Vanderwaal; April Wareham
Journal:  Trials       Date:  2022-08-19       Impact factor: 2.728

3.  Impact of treatment for opioid dependence on fatal drug-related poisoning: a national cohort study in England.

Authors:  Matthias Pierce; Sheila M Bird; Matthew Hickman; John Marsden; Graham Dunn; Andrew Jones; Tim Millar
Journal:  Addiction       Date:  2015-11-25       Impact factor: 6.526

4.  Memory-Focused Cognitive Therapy for Cocaine Use Disorder: Theory, Procedures and Preliminary Evidence From an External Pilot Randomised Controlled Trial.

Authors:  John Marsden; Camille Goetz; Tim Meynen; Luke Mitcheson; Garry Stillwell; Brian Eastwood; John Strang; Nick Grey
Journal:  EBioMedicine       Date:  2018-02-02       Impact factor: 8.143

Review 5.  Repurposing NGO data for better research outcomes: a scoping review of the use and secondary analysis of NGO data in health policy and systems research.

Authors:  Sarah C Masefield; Alice Megaw; Matt Barlow; Piran C L White; Henrice Altink; Jean Grugel
Journal:  Health Res Policy Syst       Date:  2020-06-08

6.  National administrative record linkage between specialist community drug and alcohol treatment data (the National Drug Treatment Monitoring System (NDTMS)) and inpatient hospitalisation data (Hospital Episode Statistics (HES)) in England: design, method and evaluation.

Authors:  Brian Eastwood; Colin Drummond; Emmert Roberts; James C Doidge; Katie L Harron; Matthew Hotopf; Jonathan Knight; Martin White
Journal:  BMJ Open       Date:  2020-11-26       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.